Risk of Recurrent Venous Thromboembolism After an Initial Episode: Risk Stratification and Implications for Long-term Treatment
- 170 Downloads
Purpose of Review
Venous thromboembolism (VTE) is a common condition with significant associated morbidity and mortality. Recurrent VTE after an initial episode is a preventable medical condition. The following review discusses data supporting recurrence risk estimates after an initial VTE episode as well as treatment strategies to mitigate risk of recurrent VTE.
This review particularly highlights methods for stratifying the risk of recurrent VTE and recent studies that have evaluated direct oral anticoagulants for the prevention of recurrent VTE.
Risk assessment for VTE recurrence should guide anticoagulation duration. In patients who present with unprovoked VTE events, there remains a high risk of recurrence that is significantly mitigated with extended duration anticoagulation with either a vitamin K antagonist or direct oral anticoagulant.
KeywordsVenous thromboembolic disease Deep venous thrombosis Pulmonary embolism Anticoagulation Risk assessment Recurrence
Compliance with Ethical Standards
Conflict of Interest
Vineet Agrawal and Esther S.H. Kim declare that they have no conflicts of interest.
Human Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 10.•• Kearon C, Ageno W, Cannegieter SC, Cosmi B, Geersing G-J, Kyrle PA, et al. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. J Thromb Haemost. 2016;14:1480–3 An important guideline statement from the ISTH that specifically defines provoked and unprovoked venous thromboembolism.CrossRefGoogle Scholar
- 13.Prandoni P, Noventa F, Ghirarduzzi A, Pengo V, Bernardi E, Pesavento R, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica. 2007;92:199–205.CrossRefGoogle Scholar
- 16.Douketis J, Tosetto A, Marcucci M, Baglin T, Cushman M, Eichinger S, et al. Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism. Ann Intern Med. 2010;153:523–31.CrossRefGoogle Scholar
- 49.• Chee CE, Ashrani AA, Marks RS, Petterson TM, Bailey KR, Melton LJ, et al. Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study. Blood. 2014;123:3972–8 A detailed population-based cohort study looking at trends of venous thromboembolism recurrence by cancer type.CrossRefGoogle Scholar
- 54.•• Delluc A, Antic D, Lecumberri R, Ay C, Meyer G, Carrier M. Occult cancer screening in patients with venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost. 2017;15:2076–9 Recent guideline statement from the ISTH with specific recommendations on screening for occult malignancy in patients with venous thromboembolism.CrossRefGoogle Scholar
- 56.Verhovsek M, Douketis JD, Yi Q, Shrivastava S, Tait RC, Baglin T, et al. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med. 2008;149(481–90):W94.Google Scholar
- 72.• Weitz JI, Lensing AWA, Prins MH, et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med. 2017;376:1211–22 Important reference that demonstrated the efficacy of a direct oral anticoagulant, rivaroxaban, in the extended treatment of venous thromboembolism.CrossRefGoogle Scholar
- 76.• EINSTEIN Investigators, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499–510 Important reference that demonstrated the efficacy of a direct oral anticoagulant, rivaroxaban, in treatment of venous thromboembolism.CrossRefGoogle Scholar
- 77.• Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342–52 Important reference that demonstrated the efficacy of a direct oral anticoagulant, dabigatran, in treatment of venous thromboembolism.CrossRefGoogle Scholar
- 78.• Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368:699–708 Important reference that demonstrated the efficacy of a direct oral anticoagulant, apixiban, in extended treatment of venous thromboembolism. CrossRefGoogle Scholar